Clinical trial
A Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström Macroglobulinemia
NCT05190705 is registered in ClinicalTrials.gov with Shayna Sarosiek, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström Macroglobulinemia
- Lead sponsor
- Shayna Sarosiek, MD
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 17, 2022
- Completion date
- August 1, 2028
- Enrollment
- 21 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.